Leuprolide acetate Depot Susp.

Phase 3Small molecule

Leuprolide acetate Depot Susp. is one of 94 small molecule programs targeting Lower Urinary Tract Symptom. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lower Urinary Tract SymptomActive, not recruiting

Bone Marrow TransplantationActive, not recruiting

Prostate CancerActive, not recruiting

Lower Urinary Tract SymptomPreclinical

Active, not recruiting

Bone Marrow TransplantationPhase 2

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Leuprolide acetate Depot Susp.

AAbbott

Phase 3

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Duragesic

CCephalon

Preclinical

1 7

Viagra

VViatris Specialty LLC

Preclinical

1 8

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 9

Prednisone/prednisolone

Roche

Preclinical

3 10

Triptorelin Pamoate

Ipsen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lower Urinary Tract Symptom1 trial

Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)

Completed·AAbbott··NCT01078545·729 enrolled

Bone Marrow Transplantation1 trial

A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation

Terminated·AAbbott·Phase 2·NCT00275262·25 enrolled

Prostate Cancer1 trial

A Study of Leuprolide to Treat Prostate Cancer

Completed·AAbbott·Phase 3·NCT00626431·310 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Leuprolide acetate Depot Susp.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Leuprolide acetate Depot Susp. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Leuprolide acetate Depot Susp.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Abbott company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAbbott

Leuprolide acetate Depot Susp.

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lower Urinary Tract Symptom1 trial

Bone Marrow Transplantation1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News